YujiaCai, male, Ph. D., studied at Shandong University, Chinese Academy of Sciences, and Carolinska Medical College. He received his Ph. D. from Aarhus University in Denmark in 2014. He joined Shanghai Jiao Tong University in 2017. He has been engaged in the research and development of gene therapy virus vectors, gene editing and delivery technology, as well as the interaction between gene therapy vectors and the immune system of the organism for a long time, and has devoted himself to the clinical transformation of bench-to-bedside. Patented techniques for lentivirus protein and RNA transduction have been developed. In the past five years, relevant papers have been published in eLIFE, NAR, Gene Therapy, Current Gene Therapy, JCI, EMBO J and other journals. The research project is funded by Shanghai Natural Fund, Pu Jiang Talents and Shanghai Health Planning Commission Collaborative Innovation Cluster.
